Migraine Foundation Aotearoa New Zealand welcomes
Pharmac’s Neurological Advisory Committee recommendation
that migraine-specific medications should be funded with a
high priority.
At its September meeting, the Committee
reviewed the evidence for funding galcanezumab (Emgality),
erenumab (Aimovig) and atogepant (Qulipta) for chronic and
episodic migraine. All three medications were developed
specifically to prevent migraine, and target calcitonin
gene-related peptide (CGRP), which is involved in triggering
migraine attacks.
Migraine Foundation Aotearoa New
Zealand submitted a consumer application to Pharmac to fund
Emgality in November 2022. Following the submission,
Migraine Foundation continued to engage with Pharmac about
the application. In September, Foundation members were
invited to present at the Neurological Advisory Committee
meeting.
“We’re thrilled the committee has made
this funding recommendation, and to be recommended with a
high priority is the best outcome at this stage of the
process,” Sarah Cahill, Migraine Foundation Aotearoa New
Zealand co-founder says.
“About 642,000 people in
New Zealand have migraine, and it’s the fourth largest
cause of disability in New Zealand. Until these anti- CGRP
medications were developed, people with migraine have had to
rely on medications designed to treat other conditions, such
as high blood pressure or epilepsy to try and prevent
migraine attacks. Often these have terrible side effects or
aren’t very effective.”
Advertisement – scroll to continue reading
“There are thousands of
people in New Zealand whose lives would improve
exponentially if these medications were funded. Some people
in New Zealand have been paying for one or another of these
out of pocket (two are currently on the market in New
Zealand), but for thousands of others who would benefit,
spending hundreds of dollars on a 4-weekly injection isn’t
something they can afford,” Sarah says.
One of the
CGRP medications, Aimovig, was considered for funding by
Pharmac’s PTAC in August 2021 (before Migraine Foundation
was established), and was recommended for funding with a low
priority for people with chronic migraine only.
The
high priority recommendation received for all three migraine
medications, plus the highest priority for both chronic and
episodic migraine, is a huge win for the migraine community,
and underscores the urgent need for access to
migraine-specific, effective and safe medications.
The
recommendations will now be considered by Pharmac using its
Factors for Consideration framework and internal economic
assessments. If Pharmac does decide to add these medications
to its list of ‘options for investment’ at a high
priority, it’s then a wait for Pharmac to choose to make
that investment, depending on its level of budget, and enter
into negotiations with the relevant pharmaceutical
companies.
There’s a long road ahead but it brings New
Zealand one step closer to catching up with Australia,
Canada and the UK, where anti-CGRP medications are already
available and
funded.
© Scoop Media
Advertisement – scroll to continue reading



















Discussion about this post